Celera Focusing On KIF6 Test Launch In ’09, Says Cardio Dx Products Will Grow Profits

Celera has a two-pronged strategy to grow revenues: expand physician and patient adoption of Berkeley HeartLab’s existing cardiovascular disease tests and expand its menu of new tests.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.